Victrex plc

Victrex plc

11.00
EUR
-0.70
(-5.98%)
561.95MMarket Cap
Dec 08Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.63
2.98
3.1
2.96
3.39
3.8
3.34
3.06
3.59
3.92
3.53
3.41
3.41
- -
Basic EPS, GAAP
0.86
0.95
0.98
0.97
1.16
1.29
1.07
0.63
0.84
0.88
0.71
0.2
0.32
- -
Free Cash Flow per Basic Share
0.47
0.38
0.55
0.67
1.18
1.39
0.67
0.51
0.98
0.4
0.04
0.59
0.57
- -
Dividend per Share
0.39
0.44
0.95
0.47
0.47
1.23
1.42
0.46
0.6
1.1
0.6
0.6
0.6
- -
Book Value per Share
3.7
4.15
4.2
4.55
5.57
5.69
5.34
5.52
5.85
5.62
5.73
5.3
4.98
4.15
Tangible Book Value per Share
3.58
4.03
3.96
4.28
5.22
5.37
5.02
5.21
5.57
5.39
5.52
5.1
4.79
3.96
Basic Weighted Avg Shares
84
85
85
85
85
86
86
86
87
87
87
87
87
87
Sales/Revenue/Turnover
222
253
264
252
290
326
288
265
311
341
307
296
296
- -
Operating Margin (%)
42.36
40.46
40.34
39.95
38.97
38.93
36.65
28.73
30.01
25.95
23.84
15.46
13.43
- -
Depreciation Expense
10
10
13
16
18
18
17
21
22
22
22
23
25
- -
Net Income, GAAP
73
80
84
83
100
111
92
54
73
76
62
17
28
- -
Effective Tax Rate (%)
22.94
21.91
21.52
17.75
10.36
13.25
11.75
14.65
21.3
13.91
15.86
32.48
26.33
- -
Profit Margin (%)
32.85
31.75
31.69
32.7
34.29
33.93
32.07
20.49
23.52
22.35
20.1
5.81
9.38
- -
Working Capital
141
134
105
121
188
206
159
173
182
147
173
156
124
109
LT Debt
- -
- -
- -
- -
- -
- -
- -
6
14
29
43
41
30
37
Total Equity
314
353
359
389
478
490
462
481
512
491
501
462
431
344
Return on Invested Capital (%)
23.4
22.92
22.86
21.48
22.52
22.35
18.9
11.36
14.42
14.46
11.43
5.79
5.9
- -
Return on Capital (%)
24.98
24.07
23.5
22.13
23.02
22.84
19.42
11.47
14.52
14.69
11.68
3.71
6.54
- -
Return on Common Equity (%)
24.93
24.04
23.46
22.07
22.94
22.84
19.42
11.54
14.83
15.27
12.49
3.58
6.22
- -

Capital Structure

GBP

•

in mil. unless spec.
Mar'25
Sep'25
Mar'26
ST Debt
12
19
40
LT Borrowings
47
23
31
LT Finance Leases
8
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
87
87
Market Capitalization
780
600
491

Working Capital

GBP

•

in mil. unless spec.
Mar'25
Sep'25
Mar'26
Total Current Assets
195
185
189
Cash, Cash Equivalents & STI
25
24
32
Accounts Receivable, Net
48
34
50
Inventories
114
110
106
Total Current Liabilities
51
62
81
Payables & Accruals
- -
- -
- -
ST Debt
12
19
40
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.01%
-6.59%
Free Cash Flow
148.66%
288.68%
-4.09%
Net Income, GAAP
-1.76%
1.93%
61.63%
Sales/Revenue/Turnover
1.71%
2.76%
0.07%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
296
2025
- -
- -
296
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.2
2025
- -
- -
0.32
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.6
2025
- -
- -
0.6
2026
- -
- -
- -

Company Description

CEO
James Mathew Routh
Full Time Employees
1,169
Sector
Process industries
Industry
Chemicals: major diversified
Address
Victrex Technology Centre Thornton Cleveleys LA United Kingdom FY5 4QD
IPO Date
Dec 13, 1995
Business
Victrex plc manufactures and sells high-performance PEEK and PAEK polymer solutions worldwide, including semi-finished and finished parts such as pipes, films, fibres, composite tapes and specialist medical components; it operates through Sustainable Solutions and Medical segments serving automotive, aerospace, energy and industrial, electronics, manufacturing and engineering, and medical markets. The company, founded in 1993 and headquartered in Thornton-Cleveleys, Lancashire, UK, focuses on brands including VICTREX PEEK polymers like 450G, APTIV films, AE 250 composites, PEEK-OPTIMA for medical devices, and VICTREX XPI for e-mobility applications; its products enable lightweighting, durability, chemical resistance and sustainability in over 40 countries with 98% of revenues from outside the UK. Recent developments include the commercial start-up of new manufacturing facilities in Panjin, China, during fiscal year 2024 to broaden PEEK grades and support regional growth; progression in mega-programmes such as Magma with a technological contract order from Petrobras to TechnipFMC in May 2025, Aerospace Composites business wins in Advanced Air Mobility, Trauma Plates regulatory submissions in China, and PEEK Knee with first US clinical trial implants; alongside a Profit Improvement Plan targeting at least £10m in annual savings by fiscal year 2027, impairment of investments in Bond 3D and Surface Generation, and maintenance of the dividend at 59.56p per share.

Company News

  • Victrex PLC (OTCMKTS:VTXPF) Stock Now Rated “Hold” by Wall Street Brokerages

  • Victrex plc (VTXPY) Analyst/Investor Day Prepared Remarks Transcript

  • All You Need to Know About Victrex (VTXPF) Rating Upgrade to Buy

  • Deutsche Bank lifts Victrex earnings forecasts but stays on 'hold'

  • Victrex earnings slump creates buying opportunity, says Stifel

  • Victrex plc (VTXPY) Q2 2026 Earnings Call Transcript

  • Victrex PLC (OTCMKTS:VTXPF) Short Interest Down 81.6% in January

  • Xmas stock picks wrap-up: who won the 2025 competition?

  • Victrex plc (VTXPF) Q4 2025 Earnings Call Transcript

  • Victrex plc (VTXPF) Q3 2025 Sales/ Trading Statement Call Transcript

  • Victrex plc (VTXPF) Q2 2025 Earnings Call Transcript

  • Victrex plc (VTXPF) Q4 2024 Earnings Call Transcript

  • Victrex plc (VTXPF) Q4 2023 Earnings Call Transcript

  • Victrex plc (VTXPF) Q2 2023 Earnings Call Transcript

  • Victrex Has Growth and Value

  • Victrex plc (VTXPF) Q4 2022 Earnings Call Transcript

  • Victrex PLC (VTXPF) CEO Jakob Sigurdsson on Q2 2020 Results - Earnings Call Transcript